Sees FY26 product sales $29.6B-$30B. Sees FY26 product sales excluding Veklury $29B-$29.4B.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead options imply 5.5% move in share price post-earnings
- Notable companies reporting after market close
- Invesco QQQ Trust ETF (QQQ) Daily Update, 2/10/2026
- Options Volatility and Implied Earnings Moves Today, February 10, 2026
- Reaffirming Gilead as a Buy: HIV Franchise Strength, Emerging Oncology Assets, and Strategic Capital Deployment Support $156 Target